Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Sanofi execs prep their pitch on a post-Viehbacher R&D strategy

One of the primary roles for any Big Pharma CEO is to act as a chief defender of the pipeline. Just months ago, Chris Viehbacher boldly asserted that Sanofi had one of the top 5 pipelines in the industry, if you added in some top programs among its close development partners.

Need more on ex-Sanofi CEO Viehbacher's sudden exit?

If you haven't yet read enough about ex-Sanofi CEO Chris Viehbacher's departure, check out Bloomberg' s latest.

AcelRx CEO Richard King steps down

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Venter makes new hires at Synthetic Genomics and Human Longevity

J. Craig Venter has made new hires at two of his companies.

Sanofi CEO Viehbacher ousted unanimously by its board

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Chris Viehbacher leaving Sanofi without a U.S.-style windfall

For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.

CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg

Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, Sanofi had a more literal view: The French drugmaker has contacted Soriot himself.

Sanofi canned its outspoken CEO. Will the board go French with a replacement?

CEO Chris Viehbacher's future may not have been on the Sanofi board's agenda Monday. But it was on Wednesday. The directors issued a statement after an 8 a.m. meeting, the gist of which is this: At Sanofi, he has none.

Shire CFO to exit in wake of failed AbbVie deal

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Cubist CEO Bonney hands over reins as new buyout rumors circulate

After 11 years at the helm of Cubist Pharmaceuticals, CEO Michael Bonney is stepping down and handing the reins to COO and President Robert Perez.